Invalidity dossier
US 9221897
Human cytomegalovirus neutralizing antibodies and use thereof
Current assignee: Institute for Research in Biomedicine
Added 9/21/2026, 9:32:40 AM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview: US9221897B2
Title: Human cytomegalovirus neutralizing antibodies and use thereof
Patent Number: US9221897B2
Assignee: Institute for Research in Biomedicine (IRB) — original and current assignee per the supplied listing
Inventors: Antonio Lanzavecchia and Annalisa Macagno
Key Dates:
- Priority date: 2008-07-16
- Application number: US14/096,283
- Filing date: 2013-12-04
- Publication date (as US20140193428A1): 2014-07-10
- Grant/publication date (as US9221897B2): 2015-12-29
- Anticipated expiration: 2029-07-15
- Legal status: Expired – Fee Related
Purpose and Plain-Language Scope:
The patent concerns human antibodies that neutralize human cytomegalovirus (HCMV), a DNA virus of the herpesvirus family (classification C07K16/089 — Cytomegalovirus; A61P31/22 — antivirals for herpes viruses). The classifications indicate the subject matter covers immunoglobulins against viral material, peptide medicinal preparations, and antiviral/anti-infective therapeutic uses, including antibody-containing compositions and combinations of two or more separate antibodies (A61K2039/507). The classification tags further indicate human (primate) antibody origin, defined epitope binding (including linear epitopes under 20 residues or conformational epitopes), glycosylation features, and various antibody fragments (Fab, Fab', F(ab')2, scFv, VH/VL, CDRs). The listed prior-art keywords are: antibody, seq, hcmv, antibodies, epitope. In plain terms, the patent appears directed to human-derived HCMV-neutralizing antibodies, their epitopes/sequences, and their use in treating or preventing HCMV infection. Family members referenced in the listing include US9365636B1, US9527902B2, US9796771B2, and US9796772B2.
Source: https://patents.google.com/patent/[US9221897](/patent/US9221897)/en
What this excerpt does not establish: The supplied text contains no claims, no sequence listings, no examples, no efficacy or dosing data, and no specification body. It therefore does not establish the actual claimed scope, the specific antibodies or epitopes, or any clinical use. The classification codes and keywords are metadata only and are not a legal characterization of claim scope. Litigation, ownership transfers, validity, and prior art are outside this overview and were not researched.
Generated 10/1/2026, 10:02:11 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 9221897. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.